Biotechnology

The biotechnology sector has boomed since the recession, providing substantial returns for investors in specialist funds exposed to this area.

Dotcom bubble 2.0?

Dr. Daniel Koller, head of management team, BB Biotech

Investors are showing increasing willingness to pay for R&D pipelines in biotech, explains AXA Framlington's Linden Thomson.

What’s gone wrong with global funds?

Is it worth accessing medical tech stocks via crowdfunding?

Healthcare will see ‘once-in-a-lifetime’ structural shift

The biologic drug boom

Biotech's big trends

Biotech off the beaten track